On the Pharmion call Friday one of the doc's pointed out the same thing. I believe that is one of the drugs that was mentioned he was speaking about Kidney Cancer in general.
Granted this may be biased but there appeared to be general consensus that satraplatin warrants approval just on PFS and also its by no means clear that a survival benefit won't appear.
My 2 cents Overall survival just adds extra for the benefits of an Oral Platinum with a (relatively) benign safety profile. Just to make sure the drug is successful though I'd like to see GPC and Pharmion initiate as many Phase 2's in as many indications as possible ASAP :)
Market Data 
Markets 
AI
